The Comprehensive Guide to Leuprolide 22.5 mg Injection For healthcare providers, clinics, and pharmaceutical distributors globally, Leuprolide 22.5 mg Injection is a critical, long-acting medication used to manage advanced hormone-dependent conditions. As a leading pharmaceutical exporter and bulk supplier from India, Ernest Oncology (a group of Ernest Pharmaceutical Pvt. Ltd.) ensures that this vital medication reaches medical facilities across London, New York, Sydney, Johannesburg, and the broader global market with full regulatory compliance. Product Specifications Brand Name: Ernest-Oncology (Leuprolide Acetate) Strength: 22.5 mg Dosage Form: Depot Suspension for Injection (Subcutaneous or Intramuscular) Primary Indication: Advanced prostate cancer, endometriosis, and uterine fibroids. Storage: Store at room temperature (20°C to 25°C), protect from light and moisture. Mechanism of Action: How It Works Initial Stimulation: Upon initial administration, it briefly increases the levels of certain hormones (like testosterone in men and estrogen in women). Down-Regulation: With continuous administration, it desensitizes the pituitary gland. This stops the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). Hormone Suppression: Consequently, it drastically reduces the levels of testosterone or estrogen in the body, which effectively slows or stops the growth of hormone-dependent tumors and tissues. Therapeutic Indications & Administration Advanced Prostate Cancer: Palliative treatment to reduce testosterone levels and suppress tumor progression. Endometriosis & Uterine Fibroids: Relieving pelvic pain and shrinking tissue growths in female patients. Administration: * Route: Administered as a subcutaneous or intramuscular injection by a qualified healthcare professional. Frequency: Given once every 3 months due to the extended-release depot delivery system. Clinical Side Effects & Safety Profile Hormone-Suppression Effects: Hot flashes, night sweats, fatigue, mood changes, and decreased sex drive. Bone Mineral Density Loss: Long-term use can lower bone density, carrying a risk of osteoporosis or bone fractures. Initial Tumor Flare: In the first few weeks, prostate cancer symptoms (like bone or nerve pain) may temporarily worsen before improving. Serious Warnings: Rare risks include cardiovascular events (heart attack, stroke), QT prolongation, and severe skin reactions like Stevens-Johnson syndrome. Contraindications: Contraindicated during pregnancy and breastfeeding due to the high risk of fetal harm. Why Source from Ernest Oncology? United Kingdom (London): Supplying cost-effective, high-quality oncology solutions for specialized clinics and hospitals. USA: Delivering bulk quantities that meet international safety, regulatory, and documentation standards. Australia: Ensuring stable access through established supply chains. South Africa: Bridging critical gaps in the oncology market with reliable, top-tier pharmaceutical exports from India. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD.] 📦 Business Type: Exporter | Bulk Supplier | Distributor 🌐 Websites: www.oncologymedicinesupplier.com www.ernestpharmaceuticals.com www.ernestvision.com www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📲 WhatsApp: +91 93599 02383 🔗 Direct Link: https://wa.me/919359902383
Washington, USA
08048034998
+919405476170
Chat with us
Chat with us